Ligand Pharmaceuticals Details XOMA Royalty Acquisition Impact, Raises 2026 Guidance

summarizeSummary

Ligand Pharmaceuticals provided detailed financial projections and updated 2026 guidance following its $739 million acquisition of XOMA Royalty Corporation, highlighting significant accretion to earnings and portfolio expansion.

check_boxKey Events

• Acquisition Details Confirmed

  Ligand Pharmaceuticals provided an investor presentation transcript detailing the $739 million acquisition of XOMA Royalty Corporation, expected to close in Q3 2026.

• Raised 2026 Financial Guidance

  The company increased its full-year royalty revenue guidance to $225M-$250M (from $200M-$225M) and total revenue guidance to $270M-$310M (from $245M-$285M).

• Significant EPS Accretion Projected

  Adjusted core EPS guidance for 2026 was raised to $8.50-$9.50 (from $8-$9), with the acquisition expected to add $0.50 to 2026 EPS and $1.50 to 2027 EPS.

• Portfolio Expansion and Growth Acceleration

  The acquisition will add seven commercial royalties, including key programs like Vabysmo, Ojemda, and Miplyffa, and over 100 partnered development-stage programs, more than doubling Ligand's portfolio size.

auto_awesomeAnalysis

This filing provides the detailed financial and strategic rationale behind Ligand Pharmaceuticals' recently announced $739 million acquisition of XOMA Royalty Corporation. It quantifies the expected positive impact on Ligand's financials, including a significant increase in 2026 and 2027 adjusted EPS, and raises the company's full-year royalty and total revenue guidance. The acquisition is strategically important as it substantially expands Ligand's royalty portfolio with seven new commercial assets and over 100 development-stage programs, accelerating long-term growth without shareholder dilution. The company noted that despite trading near 52-week highs, they believe their stock is undervalued, justifying the all-cash, non-dilutive funding approach.